Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Enanta Pharma (NASDAQ:ENTA)

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA) in the last three months.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish
Total Ratings	2	4
Last 30D	1	0
1M Ago	0	2
2M Ago	0	0
3M Ago	1	2

Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.67, a high estimate of $27.00, and a low estimate of $18.00. This current average has decreased by 10.93% from the previous average price target of $24.33.

Decoding Analyst Ratings: A Detailed Look

In examining recent analyst actions, we gain insights into how financial experts perceive Enanta Pharma. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Ed Arce	HC Wainwright & Co.	Lowers	Buy	$18.00	$27.00
Brian Skorney	Baird	Lowers	Outperform	$20.00	$26.00
Roy Buchanan	JMP Securities	Lowers	Market Outperform	$21.00	$22.00
Ed Arce	HC Wainwright & Co.	Maintains	Buy	$27.00	$27.00
Roy Buchanan	JMP Securities	Maintains	Market Outperform	$22.00	$22.00
Roy Buchanan	JMP Securities	Maintains	Market Outperform	$22.00	$22.00

Key Insights:

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Enanta Pharma. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Enanta Pharma compared to the broader market.
Price Targets: Analysts predict movements in price targets, offering estimates for Enanta Pharma's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Enanta Pharma's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Enanta Pharma analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Enanta Pharma Better

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Financial Insights: Enanta Pharma

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Decline in Revenue: Over the 3 months period, Enanta Pharma faced challenges, resulting in a decline of approximately -22.84% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Enanta Pharma's net margin excels beyond industry benchmarks, reaching -197.32%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Enanta Pharma's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -20.76%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Enanta Pharma's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.43%, the company may face hurdles in achieving optimal financial returns.

Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.43, caution is advised due to increased financial risk.

The Significance of Analyst Ratings Explained

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTAEnanta Pharmaceuticals Inc

$13.550.74%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.